People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | — | Biotechnology | Series C | $78.5M | $2.3B | 2020 |
Keith Regnante at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Regnante on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Alon Lazarus | 1 | 7 |
| Julius Knowles | 1 | 5 |
| Zafrira Avnur | 1 | 4 |
| Ran Nussbaum | 1 | 3 |
| JASBIR SEEHRA | 1 | 2 |
| Nima Farzan | 1 | 2 |
| Jenn Lachey | 1 | 1 |
| Claudia Ordonez | 1 | 1 |
| Julius S. Knowles | 1 | 1 |
| Zafrira S. Avnur | 1 | 1 |
| Ran S. Nussbaum | 1 | 1 |
| Alon S. Lazarus | 1 | 1 |
| Jasbir S. Seehra | 1 | 1 |
| Ohad S. Hammer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.